Abstract
Metabolic differences between normal and cancerous cells have been used as a point of view for developing anticancer drugs. Some degrading enzymes of certain amino acids have been regarded to kill cancerous cells. L-Asparaginase (ASNase) has shown an excellent therapeutic response to asparagine-auxotrophic cancers such as acute lymphoblastic leukemia (ALL). Some bacteria, yeasts, molds, plants, and animals produce ASNase. Bacterial ASNases from Escherichia coli and Erwinia chrysanthemi are the FDA-approved drugs for ALL treatment. Here, we review new natural prokaryotic and eukaryotic sources of ASNases, recent advances to introduce improvement strategies for the production of recombinant ASNases as well as their chemical modifications, immobilization, nanoencapsulation, and in silico studies to increase efficiency and decrease side effects. Recent studies for application of ASNases to treatment of asparagine-auxotrophic cancers, especially solid cancers, have been reviewed. Furthermore, challenges and future perspectives are discussed for this promising therapeutic enzyme.
Key points
• Review recent advances to introduce new sources of microbial L-asparaginases.
• Review improvement strategies for the development of stable and non-toxic L-asparaginases.
• Review microbial L-asparaginase application in various cancers’ treatment.
Graphical abstract
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abbas Ahmed MM, Nageh Abo Dahab F, Taher Taha M, Fareed Hassan SM (2015) Production, purification and characterization of L-asparaginase from marine endophytic Aspergillus sp. ALAA-2000 under submerged and solid state fermentation. J Microb Biochem Technol 7:165–172. https://doi.org/10.4172/1948-5948.1000199
Al-Dulimi AG, Al-Saffar AZ, Sulaiman GM, Khalil KA, Khashan KS, Al-Shmgani HS, Ahmed EM (2020) Immobilization of L-asparaginase on gold nanoparticles for novel drug delivery approach as anti-cancer agent against human breast carcinoma cells. J Mater Res Technol 9(6):15394–15411. https://doi.org/10.1016/j.jmrt.2020.10.021
Ardalan N, Mirzaie S, Sepahi AA, Khavari-Nejad RA (2018) Novel mutant of Escherichia coli asparaginase II to reduction of the glutaminase activity in treatment of acute lymphocytic leukemia by molecular dynamics simulations and QM-MM studies. Med Hypotheses 112:7–17. https://doi.org/10.1016/j.mehy.2018.01.004
Ashok A, Doriya K, Rao JV, Qureshi A, Tiwari AK, Kumar DS (2019) Microbes producing L-asparaginase free of glutaminase and urease isolated from extreme locations of antarctic soil and moss. Sci Rep 9(1):1–10. https://doi.org/10.1038/s41598-018-38094-1
Bachet JB, Gay F, Maréchal R, Galais MP, Adenis A, David Salako M, Cros J, Demetter P, Svrcek M, Bardier-Dupas A, Emile JF (2015) Asparagine synthetase expression and phase I study with L-asparaginase encapsulated in red blood cells in patients with pancreatic adenocarcinoma. Pancreas 44(7):1141–1147. https://doi.org/10.1097/MPA.0000000000000394
Baig MH, Adil M, Khan R, Dhadi S, Ahmad K, Rabbani G, Bashir T, Imran MA, Husain FM, Lee EJ, Kamal MA (2019) Enzyme targeting strategies for prevention and treatment of cancer: implications for cancer therapy. Semin Cancer Biol 56:1–11. https://doi.org/10.1016/j.semcancer.2017.12.003
Baral A, Gorkhali R, Basnet A, Koirala S, Bhattarai HK (2020) In-silico development of a method for the selection of optimal enzymes using L-asparaginase II against acute lymphoblastic leukemia as an example. Jmirx Med 2(3):e29844. https://doi.org/10.2196/29844
Baskar G, Lalitha K, Bikku George G (2019) Synthesis, characterization and anticancer activity of selenium nanobiocomposite of L-asparaginase. Bull Mate Sci 42(1):4. https://doi.org/10.1007/s12034-018-1686-z
Belviso S, Iuliano R, Amato R, Perrotti N, Menniti M (2017) The human asparaginase enzyme (ASPG) inhibits growth in leukemic cells. PLoS ONE 12(5):e0178174. https://doi.org/10.1371/journal.pone.0178174
Binder U, Skerra A (2017) PASylation®: a versatile technology to extend drug delivery. Curr Opin Colloid Interface Sci 31:10–17. https://doi.org/10.1016/j.cocis.2017.06.004
Blackman LD, Varlas S, Arno MC, Houston ZH, Fletcher NL, Thurecht KJ, Hasan M, Gibson MI, O’Reilly RK (2018) Confinement of therapeutic enzymes in selectively permeable polymer vesicles by polymerization-induced self-assembly (PISA) reduces antibody binding and proteolytic susceptibility. ACS Cent Sci 4(6):718–723. https://doi.org/10.1021/acscentsci.8b00168
Brumano LP, da Silva FV, Costa-Silva TA, Apolinário AC, Santos JH, Kleingesinds EK, Monteiro G, Rangel-Yagui CD, Benyahia B, Junior AP (2019) Development of L-asparaginase biobetters: current research status and review of the desirable quality profiles. Front Bioeng Biotechnol 6:212. https://doi.org/10.3389/fbioe.2018.00212
Chiu M, Taurino G, Bianchi MG, Kilberg MS, Bussolati O (2019) Asparagine synthetase in cancer: beyond acute lymphoblastic leukemia. Front Oncol 9:1480. https://doi.org/10.3389/fonc.2019.01480
Chu DT, Nguyen TT, Tien NL, Tran DK, Jeong JH, Anh PG, Thanh VV, Truong DT, Dinh TC (2020) Recent progress of stem cell therapy in cancer treatment: molecular mechanisms and potential applications. Cells 9(3):563. https://doi.org/10.3390/cells9030563
Chulpanova DS, Kitaeva KV, Tazetdinova LG, James V, Rizvanov AA, Solovyeva VV (2018) Application of mesenchymal stem cells for therapeutic agent delivery in anti-tumor treatment. Front Pharmacol 9:259. https://doi.org/10.3389/fphar.2018.00259
Costa-Silva TA, Costa IM, Biasoto HP, Lima GM, Silva C, Pessoa A, Monteiro G (2020) Critical overview of the main features and techniques used for the evaluation of the clinical applicability of L-asparaginase as a biopharmaceutical to treat blood cancer. Blood Rev 43:100651. https://doi.org/10.1016/j.blre.2020.100651
Darvishi F (2014) Biotechnological applications of the yeast Yarrowia lipolytica. Springer, New York. https://doi.org/10.1007/978-3-319-06437-6
Darvishi F, Ariana M, Marella ER, Borodina I (2018) Advances in synthetic biology of oleaginous yeast Yarrowia lipolytica for producing non-native chemicals. Appl Microbiol Biotechnol 102(14):5925–5938. https://doi.org/10.1007/s00253-018-9099-x
Darvishi F, Faraji N, Shamsi F (2019) Production and structural modeling of a novel asparaginase in Yarrowia lipolytica. Int J Biol Macromol 125:955–961. https://doi.org/10.1016/j.ijbiomac.2018.12.162
Darvishi F, Shamsi F (2018) Investigating the L-asparaginase production in the yeast Yarrowia lipolytica. Biological J Microorganisms 7(27):73–79. https://doi.org/10.22108/BJM.2018.111339.1133
Dhankhar R, Gupta V, Kumar S, Kapoor RK, Gulati P (2020) Microbial enzymes for deprivation of amino acid metabolism in malignant cells: biological strategy for cancer treatment. Appl Microbiol Biotechnol 104(7):2857–2869. https://doi.org/10.1007/s00253-020-10432-2
Dias FF, Ruiz AL, Della Torre A, Sato HH (2016) Purification, characterization and antiproliferative activity of L-asparaginase from Aspergillus oryzae CCT 3940 with no glutaminase activity. Asian Pac J Trop Biomed 6(9):785–794. https://doi.org/10.1016/j.apjtb.2016.07.007
Do TT, Do TP, Nguyen TN, Nguyen TC, Vu TT, Nguyen TG (2019) Nanoliposomal L-asparaginase and its antitumor activities in lewis lung carcinoma tumor-induced BALB/c mice. Adv Mater Sci Eng 2019:3534807. https://doi.org/10.1155/2019/3534807
Doriya K, Kumar DS (2016) Isolation and screening of L-asparaginase free of glutaminase and urease from fungal sp 3. Biotech 6(2):1–10. https://doi.org/10.1007/s13205-016-0544-1
Duval M, Suciu S, Ferster A, Rialland X, Nelken B, Lutz P, Benoit Y, Robert A, Manel AM, Vilmer E, Otten J (2002) Comparison of Escherichia coli–asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer—children’s leukemia group phase 3 trial. Blood 99(8):2734–2739. https://doi.org/10.1182/blood.v99.8.2734
El-Gendy MM, Awad MF, El-Shenawy FS, El-Bondkly AM (2021) Production, purification, characterization, antioxidant and antiproliferative activities of extracellular L-asparaginase produced by Fusarium equiseti AHMF4. Saudi J Biol Sci 28:2540–2548. https://doi.org/10.1016/j.sjbs.2021.01.058
El-Naggar NE, Deraz SF, Soliman HM, El-Deeb NM, El-Ewasy SM (2016) Purification, characterization, cytotoxicity and anticancer activities of L-asparaginase, anti-colon cancer protein, from the newly isolated alkaliphilic Streptomyces fradiae NEAE-82. Sci Rep 6(1):1–16. https://doi.org/10.1038/srep32926
El-Naggar NE, El-Shweihy NM (2020) Bioprocess development for L-asparaginase production by Streptomyces rochei, purification and in-vitro efficacy against various human carcinoma cell lines. Sci Rep 10:7942. https://doi.org/10.1038/s41598-020-64052-x
Emadi A, Law JY, Strovel ET, Lapidus RG, Jeng LJ, Lee M, Blitzer MG, Carter-Cooper BA, Sewell D, Van Der Merwe I, Philip S (2018) Asparaginase Erwinia chrysanthemi effectively depletes plasma glutamine in adult patients with relapsed/refractory acute myeloid leukemia. Cancer Chemother Pharmacol 81(1):217–222. https://doi.org/10.1007/s00280-017-3459-6
Fatima N, Khan MM, Khan IA (2019) L-Asparaginase produced from soil isolates of Pseudomonas aeruginosa shows potent anti-cancer activity on HeLa cells. Saudi J Biol Sci 26:1146–1153. https://doi.org/10.1016/j.sjbs.2019.05.001
Garcia-Bermudez J, Williams RT, Guarecuco R, Birsoy K (2020) Targeting extracellular nutrient dependencies of cancer cells. Mol Metab 33:67–82. https://doi.org/10.1016/j.molmet.2019.11.011
Geddes WF, Hunter A (1928) Observations upon the enzyme asparaginase. J Biol Chem 77(1):197–229. https://doi.org/10.1016/S0021-9258(18)84052-2
Ghasemian A, Al-marzoqi AH, Al-abodi HR, Alghanimi YK, Kadhum SA, Shokouhi Mostafavi SK, Fattahi A (2019) Bacterial L-asparaginases for cancer therapy: current knowledge and future perspectives. J Cell Physiol 234(11):1–9. https://doi.org/10.1002/jcp.28563
Hammel P, Fabienne P, Mineur L, Metges JP, Andre T, De La Fouchardiere C, Louvet C, El Hajbi F, Faroux R, Guimbaud R, Tougeron D (2020) Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: an open-label, randomized phase IIb trial. Eur J Cancer 124:91–101. https://doi.org/10.1016/j.ejca.2019.10.020
Hasan H, Shaikh OM, Rassekh SR, Howard AF, Goddard K (2016) Comparison of hypersensitivity rates to intravenous and intramuscular PEG-asparaginase in children with acute lymphoblastic leukemia: a meta-analysis and systematic review. Pediatr Blood Cancer 64(1):81–88. https://doi.org/10.1002/pbc.26200
Isaac GS, Abu-Tahon MA (2016) Production of extracellular anti-leukemic enzyme L-asparaginase from Fusarium solani AUMC 8615 grown under solid-state fermentation conditions: purification and characterization of the free and immobilized enzyme. Egypt J Bot 56:799–816. https://doi.org/10.21608/EJBO.2016.3776
Jahanafrooz Z, Baradaran B, Mosafer J, Hashemzaei M, Rezaei T, Mokhtarzadeh A, Hamblin MR (2019) Comparison of DNA and mRNA vaccines against cancer. Drug Discov Today 25(3):552–560. https://doi.org/10.1016/j.drudis.2019.12.003
Jahanafrooz Z, Mosafer J, Akbari M, Hashemzaei M, Mokhtarzadeh A, Baradaran B (2020) Colon cancer therapy by focusing on colon cancer stem cells and their tumor microenvironment. J Cell Physiol 235(5):4153–4166. https://doi.org/10.1002/jcp.29337
Jiao L, Chi H, Lu Z, Zhang C, Chia SR, Show PL, Tao Y, Lu F (2020) Characterization of a novel type I l-asparaginase from Acinetobacter soli and its ability to inhibit acrylamide formation in potato chips. J Biosci Bioeng 129(6):672–678. https://doi.org/10.1016/j.jbiosc.2020.01.007
Johansson O, Ward M (2017) The human immune system’s response to carcinogenic and other infectious agents transmitted by mosquito vectors. Parasitol Res 116:1–9. https://doi.org/10.1007/s00436-016-5272-2
Krishnapura PR, Belur PD, Subramanya S (2016) A critical review on properties and applications of microbial L-asparaginases. Crit Rev Microbiol 42(5):720–737. https://doi.org/10.3109/1040841X.2015.1022505
Lee-Six H, Olafsson S, Ellis P, Osborne RJ, Sanders MA, Moore L, Georgakopoulos N, Torrente F, Noorani A, Goddard M, Robinson P (2019) The landscape of somatic mutation in normal colorectal epithelial cells. Nature 574(7779):532–537. https://doi.org/10.1038/s41586-019-1672-7
Lemal R, Tournilhac O (2019) State-of-the-art for CAR T-cell therapy for chronic lymphocytic leukemia in 2019. J Immunother Cancer 7:202. https://doi.org/10.1186/s40425-019-0686-x
Li RJ, Jin R, Liu C, Cao X, Manning ML, Di XM, Przepiorka D, Namuswe F, Deisseroth A, Goldberg KB, Blumenthal GM (2020) FDA approval summary: calaspargase pegol-mknl for treatment of acute lymphoblastic leukemia in children and young adults. Clin Cancer Res 26(2):328–331. https://doi.org/10.1158/1078-0432.CCR-19-1255
Lima GM, Effer B, Biasoto HP, Feijoli V, Pessoa A, Palmisano G, Monteiro G (2020) Glycosylation of L-asparaginase from E. coli through yeast expression and site-directed mutagenesis. Biochem Eng J 156:10751. https://doi.org/10.1016/j.bej.2020.107516
Lin W, Huang L, Li Y, Fang B, Li G, Chen L, Xu L (2019) Mesenchymal stem cells and cancer: clinical challenges and opportunities. Biomed Res Int 2019:2820853. https://doi.org/10.1155/2019/2820853
Liu J, Zhang X, Zhong JF, Zhang C (2017) CAR-T cells and allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia. Immunotherapy 9(13):1115–1125. https://doi.org/10.2217/imt-2017-0072
Liu Z, Moradi H, Shi S, Darvishi F (2021) Yeasts as microbial cell factories for sustainable production of biofuels. Renew Sustain Energy Rev 143:110907. https://doi.org/10.1016/j.rser.2021.110907
Lukey MJ, Katt WP, Cerione RA (2017) Targeting amino acid metabolism for cancer therapy. Drug Discov Today 22(5):796–804. https://doi.org/10.1016/j.drudis.2016.12.003
Maggi M, Mittelman SD, Parmentier JH, Colombo G, Meli M, Whitmire JM, Merrell DS, Whitelegge J, Scotti C (2017) A protease-resistant Escherichia coli asparaginase with outstanding stability and enhanced anti-leukaemic activity in vitro. Sci Rep 7:14479. https://doi.org/10.1038/s41598-017-15075-4
Mahajan RV, Kumar V, Rajendran V, Saran S, Ghosh PC, Saxena RK (2014) Purification and characterization of a novel and robust L-asparaginase having low-glutaminase activity from Bacillus licheniformis: in vitro evaluation of anticancerous properties. PLoS ONE 9(6):e99037. https://doi.org/10.1371/journal.pone.0099037
Martino AT, Markusic DM (2020) Immune response mechanisms against AAV vectors in animal models. Mol Ther - Methods Clin Dev 17:198–208. https://doi.org/10.1016/j.omtm.2019.12.008
Mashburn LT, Wriston JC (1964) Tumor inhibitory effect of L-asparaginase from Escherichia coli. Arch Biochem Biophys 105:450–452. https://doi.org/10.1016/0003-9861(64)90032-3
Mazloum-Ravasan S, Madadi E, Fathi Z, Mohammadi A, Mosafer J, Mansoori B, Mokhtarzadeh A, Baradaran B, Darvishi F (2020) The effect of Yarrowia lipolytica L-asparaginase on apoptosis induction and inhibition of growth in Burkitt’s lymphoma Raji and acute lymphoblastic leukemia MOLT-4 cells. Int J Biol Macromol 146:193–201. https://doi.org/10.1016/j.ijbiomac.2019.12.156
Mazloum-Ravasan S, Madadi E, Mohammadi A, Mansoori B, Amini M, Mokhtarzadeh A, Baradaran B, Darvishi F (2021) Yarrowia lipolytica L-asparaginase inhibits the growth and migration of lung (A549) and breast (MCF7) cancer cells. Int J Biol Macromol 170:406–414. https://doi.org/10.1016/j.ijbiomac.2020.12.141
Meena B, Anburajan L, Dheenan PS, Begum M, Vinithkumar NV, Dharani G, Kirubagaran R (2015) Novel glutaminase free L-asparaginase from Nocardiopsis alba NIOT-VKMA08: production, optimization, functional and molecular characterization. Bioproc Biosystems Eng 38(2):373–388. https://doi.org/10.1007/s00449-014-1277-3
Meena B, Anburajan L, Sathish T, Vijaya Raghavan R, Dharani G, Valsalan Vinithkumar N, Kirubagaran R (2015) L-Asparaginase from Streptomyces griseus NIOT-VKMA29: optimization of process variables using factorial designs and molecular characterization of L-asparaginase gene. Sci Rep 5(1):1–12. https://doi.org/10.1038/srep12404
Merli P, Algeri M, Del Bufalo F, Locatelli F (2019) Hematopoietic stem cell transplantation in pediatric acute lymphoblastic leukemia. Curr Hematol Malig Rep 14(2):94–105. https://doi.org/10.1007/s11899-019-00502-2
Moguel IS, Yamakawa CK, Pessoa A Jr, Mussatto SI (2020) L-Asparaginase production by Leucosporidium scottii in a bench-scale bioreactor with co-production of lipids. Front Bioeng Biotechnol 8:576511. https://doi.org/10.3389/fbioe.2020.576511
Mohideen AKS (2020) Molecular docking study of L-asparaginase I from Vibrio campbellii in the treatment of acute lymphoblastic leukemia (ALL). EuroBiotech J 4(1):8–16. https://doi.org/10.2478/ebtj-2020-0002
Mu W, Chu Q, Liu Y, Zhang N (2020) A review on nano-based drug delivery system for cancer chemoimmunotherapy. Nano-Micro Lett 12:142. https://doi.org/10.1007/s40820-020-00482-6
Muneer F, Siddique MH, Azeem F, Rasul I, Muzammil S, Zubair M, Afzal M, Nadeem H (2020) Microbial l-asparaginase: purification, characterization and applications. Arch Microbiol 202(5):967–981. https://doi.org/10.1007/s00203-020-01814-1
Nguyen H, Su AY, Lavie A (2016) Design and characterization of Erwinia chrysanthemi L-asparaginase variants with diminished l-glutaminase activity. J Biol Chem 291(34):17664–17676. https://doi.org/10.1074/jbc.M116.728485
Orhan H, Aktaş Uygun D (2020) Immobilization of L-asparaginase on magnetic nanoparticles for cancer treatment. Appl Biochem Biotechnol 191:1432–1443. https://doi.org/10.1007/s12010-020-03276-z
Patel B, Kirkwood AA, Dey A, Marks DI, McMillan AK, Menne TF, Micklewright L, Patrick P, Purnell S, Rowntree CJ, Smith P (2017) Pegylated-asparaginase during induction therapy for adult acute lymphoblastic leukaemia: toxicity data from the UKALL14 trial. Leukemia 3(1):58–64. https://doi.org/10.1038/leu.2016.219
Pillaca-Pullo O, Rodrigues D, Sánchez-Moguel I, Lopes A, Pimenta M, Basi T, Feitosa V, Iris Zavaleta A, Monteiro G, Pessoa A Jr, Vitolo M (2021) Recombinant L-asparaginase production using Pichia pastoris (MUT s strain): establishment of conditions for growth and induction phases. J Chem Technol Biotechnol 96(1):283–292. https://doi.org/10.1002/jctb.6540
Poznansky MJ, Shandling M, Salkie MA, Elliott J, Lau E (1982) Advantages in the use of L-asparaginase-albumin polymer as an antitumor agent. Cancer Res 42(3):1020–1025
Rigouin C, Nguyen HA, Schalk AM, Lavie A (2017) Discovery of human-like L-asparaginases with potential clinical use by directed evolution. Sci Rep 7(1):1–13. https://doi.org/10.1038/s41598-017-10758-4
Rodrigues D, Pillaca-Pullo O, Torres-Obreque K, Flores-Santos J, Sánchez-Moguel I, Pimenta MV, Basi T, Converti A, Lopes AM, Monteiro G, Fonseca LP (2019) Fed-batch production of Saccharomyces cerevisiae L-asparaginase II by recombinant Pichia pastoris MUTs strain. Front Bioeng Biotechnol 7:16. https://doi.org/10.3389/fbioe.2019.00016
Roth G, Nunes JE, Rosado LA, Bizarro CV, Volpato G, Nunes CP, Renard G, Basso LA, Santos DS, Chies JM (2013) Recombinant Erwinia carotovora l-asparaginase II production in Escherichia coli fed-batch cultures. Braz J Chem Eng 30(2):245–256. https://doi.org/10.1590/S0104-66322013000200003
Saeed H, Ali H, Soudan H, Embaby A, El-Sharkawy A, Farag A, Hussein A, Ataya F (2018) Molecular cloning, structural modeling and production of recombinant Aspergillus terreus L-asparaginase in Escherichia coli. Int J Biol Macromol 106:1041–1051. https://doi.org/10.1016/j.ijbiomac.2017.08.110
Sahoo S, Hart J (2003) Histopathological features of L-asparaginase–induced liver disease. Semin Liver Dis 23(3):295–299. https://doi.org/10.1055/s-2003-42647
Sajitha S, Vidya J, Binod P, Pandey A (2015) Cloning and expression of l-asparaginase from E. coli in eukaryotic expression system. Biochem Eng J 102:14–17. https://doi.org/10.1016/j.bej.2015.02.027
Scotti C, Sommi P, Pasquetto MV, Cappelletti D, Stivala S, Mignosi P, Savio M, Chiarelli LR, Valentini G, Bolanos-Garcia VM, Merrell DS (2010) Cell-cycle inhibition by Helicobacter pylori L-asparaginase. PLoS ONE 5(11):e13892. https://doi.org/10.1371/journal.pone.0013892
Shem-Tov N, Peczynski C, Labopin M, Itälä-Remes M, Blaise D, Labussière-Wallet H, Socié G, Kröger N, Mielke S, Afanasyev B, Chevallier P (2020) Haploidentical vs unrelated allogeneic stem cell transplantation for acute lymphoblastic leukemia in first complete remission: on behalf of the ALWP of the EBMT. Leukemia 3(1):283–292. https://doi.org/10.1038/s41375-019-0544-3
Shiromizu S, Kusunose N, Matsunaga N, Koyanagi S, Ohdo S (2018) Optimizing the dosing schedule of L-asparaginase improves its antitumor activity in breast tumor-bearing mice. J Pharmacol Sci 136:228e233. https://doi.org/10.1016/j.jphs.2018.01.008
Sindhu R, Manonmani HK (2018) l-Asparaginase induces intrinsic mitochondrial-mediated apoptosis in human gastric adenocarcinoma cells and impedes tumor progression. Biochem Biophys Res Commun 503(4):2393–2399. https://doi.org/10.1016/j.bbrc.2018.06.167
Song P, Wang Z, Zhang X, Fan J, Li Y, Chen Q, Wang S, Liu P, Luan J, Ye L, Ju D (2017) The role of autophagy in asparaginase-induced immune suppression of macrophages. Cell Death Dis 8(3):e2721. https://doi.org/10.1038/cddis.2017.144
Song P, Ye L, Fan J, Li Y, Zeng X, Wang Z, Wang S, Zhang G, Yang P, Cao Z, Ju D (2015) Asparaginase induces apoptosis and cytoprotective autophagy in chronic myeloid leukemia cells. Oncotarget 6(6):3861. https://doi.org/10.18632/oncotarget.2869
Triplett T, Garrison K, Marshall N (2018) Reversal of indoleamine 2,3-dioxygenase–mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme. Nat Biotechnol 36:758–764. https://doi.org/10.1038/nbt.4180
Vimal A, Kumar A (2017) Biotechnological production and practical application of L-asparaginase enzyme. Biotechnol Genet Eng Rev 33(1):40–61. https://doi.org/10.1080/02648725.2017.1357294
Wang Q, Hardie RA, Hoy AJ, Van Geldermalsen M, Gao D, Fazli L, Sadowski MC, Balaban S, Schreuder M, Nagarajah R, Wong JJ (2015) Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development. J Pathol 236(3):278–289. https://doi.org/10.1002/path.4518
Wlodarczyk SR, Costa-Silva TA, Pessoa-Jr A, Madeira P, Monteiro G (2019) Effect of osmolytes on the activity of anti-cancer enzyme L-asparaginase II from Erwinia chrysanthemi. Process Biochem 81:123–131. https://doi.org/10.1016/j.procbio.2019.03.009
Yari M, Eslami M, Ghoshoon MB, Nezafat N, Ghasemi Y (2019) Decreasing the immunogenicity of Erwinia chrysanthemi asparaginase via protein engineering: computational approach. Mol Biol Rep 46(5):4751–4761. https://doi.org/10.1007/s11033-019-04921-5
Yu M, Henning R, Walker A, Kim G, Perroy A, Alessandro R, Virador V, Kohn EC (2012) L-Asparaginase inhibits invasive and angiogenic activity and induces autophagy in ovarian cancer. J Cell Mol Med 16(10):2369–2378. https://doi.org/10.1111/j.1582-4934.2012.01547.x
Author information
Authors and Affiliations
Contributions
FD provided conception of this review, wrote and edited the manuscript. ZJ wrote and edited the manuscript. AM edited the manuscript. All authors contributed to the manuscript and approved the submitted version.
Corresponding authors
Ethics declarations
Ethics approval
This article does not contain any studies with human participants or animals.
Competing interests
The authors declare no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Darvishi, F., Jahanafrooz, Z. & Mokhtarzadeh, A. Microbial L-asparaginase as a promising enzyme for treatment of various cancers. Appl Microbiol Biotechnol 106, 5335–5347 (2022). https://doi.org/10.1007/s00253-022-12086-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00253-022-12086-8